polyclonal anti eltd1  (Bioss)

Journal: Journal of Cellular and Molecular Medicine

Article Title: Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model

doi: 10.1111/jcmm.14867

Figure Lengend Snippet: Monoclonal anti‐ELTD1 treatment is more effective in increasing animal survival and decreasing tumour volumes (TV). A, Per cent survival curve for all treatment groups; untreated control. pAb and mAb treatments were able to significantly increase the overall survival post‐tumour detection. B, Tumour volumes of each treatment group 9 days post‐tumour detection. pAb and mAb treatment significantly decreased TV compared with UT (* P = .0384, ** P = .0067). Representative morphological MR images for untreated (C), pAb treatment (D) and mAb treatment (E) 9 d post‐tumour detection with the tumour outlined in yellow

Article Snippet: Once tumours reached 6‐7 mm 3 (determined via MRI), mice were either left UT or were treated with 2 mg/kg of either polyclonal anti‐ELTD1 (Bioss, ETL/ELTD1 Polyclonal Antibody, bs‐13111R) or an optimized mAb against ELTD1 every 3‐4 days (treated M/Th, T/F, W/Sat).

Techniques:

Journal: Journal of Cellular and Molecular Medicine

Article Title: Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model

doi: 10.1111/jcmm.14867

Figure Lengend Snippet: Monoclonal anti‐ELTD1 treatment normalizes vasculature within the tumour. Representative morphological images with respective MR perfusion maps for each treatment group at tumour maximum volume (TV:120‐160 mm 2 ): untreated control (A,B), pAb‐treated animals (C,D) and mAb‐treated animals (E,F). G, Quantitative analysis of tumour rCBF differences. The rCBF perfusion levels were significantly increased with both anti‐ELTD1 treatments. The mAb treatment was also able to normalize the perfusion levels (*** P = .0001 UT vs pAb, **** P < .0001 UT vs mAb)

Article Snippet: Once tumours reached 6‐7 mm 3 (determined via MRI), mice were either left UT or were treated with 2 mg/kg of either polyclonal anti‐ELTD1 (Bioss, ETL/ELTD1 Polyclonal Antibody, bs‐13111R) or an optimized mAb against ELTD1 every 3‐4 days (treated M/Th, T/F, W/Sat).

Techniques:

Journal: Journal of Cellular and Molecular Medicine

Article Title: Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model

doi: 10.1111/jcmm.14867

Figure Lengend Snippet: Anti‐ELTD1 antibody therapy is effective in decreasing the microvessel density (MVD). Representative IHC images (20×) for CD34 from untreated (A), polyclonal anti‐ELTD1 (pAb)‐treated (B) and monoclonal anti‐ETLD1 (mAb)‐treated animals (C) at tumour maximum volume (TV 120‐160 mm 2 ). Dark red/brown staining in the slides represents vessels in the tumour region highlighted by the arrows. D, MVD analysis for all of the treatment groups. The pAb and mAb treatments were able to significantly decrease MVD (**** P < .0001 for both). There was also a significant decrease in MVD for the mAb vs the pAb (** P < .01)

Article Snippet: Once tumours reached 6‐7 mm 3 (determined via MRI), mice were either left UT or were treated with 2 mg/kg of either polyclonal anti‐ELTD1 (Bioss, ETL/ELTD1 Polyclonal Antibody, bs‐13111R) or an optimized mAb against ELTD1 every 3‐4 days (treated M/Th, T/F, W/Sat).

Techniques: Staining

Journal: Journal of Cellular and Molecular Medicine

Article Title: Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model

doi: 10.1111/jcmm.14867

Figure Lengend Snippet: mAb ELTD1 probe has significantly higher binding specificity against the tumour. A, Molecular probe construct. Gd‐DTPA signal was used to detect the probe via MR imaging while the biotin tag allowed for localization in the tumour tissue post‐termination. B, Per cent relative expression of our molecular probes indicates a change in either T1 Relaxation or SI due to the presence of the Gd‐DTPA component. The mAb‐attached probe had significantly higher signal intensity and T1 relaxation time than the IgG control (T1: * P = .0307 (IgG vs pAb ELTD1 probe), *** P = .0002 (IgG vs mAb ELTD1 probe); SI: ** P = .008 (IgG vs mAb ELTD1 probe)), (C, D) localization and clustering of our monoclonal‐attached molecular probes (C) and non‐specific IgG‐attached molecular probe (D). E, Kinetics of the antibody‐attached probes, non‐specific IgG control, pAb and mAb against ELTD1. F‐H, Representative images (20×) stained with SA‐HRP to localize the non‐specific IgG‐attached probes (F), pAb‐attached probe (G) and mAb‐attached probe (H) at tumour maximum (TV: 120‐160 mm 2 ). The brown staining seen in the pAb‐ and mAb‐attached probes is the localized probes

Article Snippet: Once tumours reached 6‐7 mm 3 (determined via MRI), mice were either left UT or were treated with 2 mg/kg of either polyclonal anti‐ELTD1 (Bioss, ETL/ELTD1 Polyclonal Antibody, bs‐13111R) or an optimized mAb against ELTD1 every 3‐4 days (treated M/Th, T/F, W/Sat).

Techniques: Binding Assay, Construct, Imaging, Expressing, Staining

Journal: Journal of Cellular and Molecular Medicine

Article Title: Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model

doi: 10.1111/jcmm.14867

Figure Lengend Snippet: mAb treatment against ELTD1 decrease Notch1 levels. A‐D, Representative images (20×) of IHC stained tumours with Notch1 of untreated (A), pAb treatment (B), mAb treated (C) and contralateral control (D). E, Quantitative positivity Notch staining of the samples. mAb against ELTD1‐treated mice significantly lowered Notch levels when compared to both untreated and pAb‐treated animals. There was no significant difference between untreated vs pAb treatment, and mAb treatment and contralateral (healthy control). Contralateral (Cont) tissue Notch levels were significantly lower than untreated mice and pAb‐treated animals (* P = .0357 (mAb vs pAb), ** P = .0015 (Cont vs pAb), *** P = .0006 (UT vs mAb), **** P < .0001 (UT vs Cont))

Article Snippet: Once tumours reached 6‐7 mm 3 (determined via MRI), mice were either left UT or were treated with 2 mg/kg of either polyclonal anti‐ELTD1 (Bioss, ETL/ELTD1 Polyclonal Antibody, bs‐13111R) or an optimized mAb against ELTD1 every 3‐4 days (treated M/Th, T/F, W/Sat).

Techniques: Staining

Journal: Journal of Cellular and Molecular Medicine

Article Title: Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model

doi: 10.1111/jcmm.14867

Figure Lengend Snippet: A, Gene‐fold changes when comparing ELTD1 mAb‐treated mice to UT from up‐regulated (red) to down‐regulated (blue), obtained from RNA‐seq analysis. B, Gene‐gene correlations for the genes repressed after anti‐ELT1 mAb treatment. Red = positively correlated, green = negatively correlated. Using literature analysis software to categorize the groups of genes in terms of their published commonalities, they roughly fall into four categories (developmental genes, nestin‐related, cell proliferation/angiogenesis, astrocyte microglia inflammation)

Article Snippet: Once tumours reached 6‐7 mm 3 (determined via MRI), mice were either left UT or were treated with 2 mg/kg of either polyclonal anti‐ELTD1 (Bioss, ETL/ELTD1 Polyclonal Antibody, bs‐13111R) or an optimized mAb against ELTD1 every 3‐4 days (treated M/Th, T/F, W/Sat).

Techniques: RNA Sequencing Assay, Software

Journal: Journal of Cellular and Molecular Medicine

Article Title: Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model

doi: 10.1111/jcmm.14867

Figure Lengend Snippet: Monoclonal anti‐ELTD1 treatment is more effective in increasing animal survival and decreasing tumour volumes (TV). A, Per cent survival curve for all treatment groups; untreated control. pAb and mAb treatments were able to significantly increase the overall survival post‐tumour detection. B, Tumour volumes of each treatment group 9 days post‐tumour detection. pAb and mAb treatment significantly decreased TV compared with UT (* P = .0384, ** P = .0067). Representative morphological MR images for untreated (C), pAb treatment (D) and mAb treatment (E) 9 d post‐tumour detection with the tumour outlined in yellow

Article Snippet: Once tumours reached 6‐7 mm 3 (determined via MRI), mice were either left UT or were treated with 2 mg/kg of either polyclonal anti‐ELTD1 (Bioss, ETL/ELTD1 Polyclonal Antibody, bs‐13111R) or an optimized mAb against ELTD1 every 3‐4 days (treated M/Th, T/F, W/Sat).

Techniques:

Journal: Journal of Cellular and Molecular Medicine

Article Title: Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model

doi: 10.1111/jcmm.14867

Figure Lengend Snippet: Monoclonal anti‐ELTD1 treatment normalizes vasculature within the tumour. Representative morphological images with respective MR perfusion maps for each treatment group at tumour maximum volume (TV:120‐160 mm 2 ): untreated control (A,B), pAb‐treated animals (C,D) and mAb‐treated animals (E,F). G, Quantitative analysis of tumour rCBF differences. The rCBF perfusion levels were significantly increased with both anti‐ELTD1 treatments. The mAb treatment was also able to normalize the perfusion levels (*** P = .0001 UT vs pAb, **** P < .0001 UT vs mAb)

Article Snippet: Once tumours reached 6‐7 mm 3 (determined via MRI), mice were either left UT or were treated with 2 mg/kg of either polyclonal anti‐ELTD1 (Bioss, ETL/ELTD1 Polyclonal Antibody, bs‐13111R) or an optimized mAb against ELTD1 every 3‐4 days (treated M/Th, T/F, W/Sat).

Techniques:

Journal: Journal of Cellular and Molecular Medicine

Article Title: Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model

doi: 10.1111/jcmm.14867

Figure Lengend Snippet: Anti‐ELTD1 antibody therapy is effective in decreasing the microvessel density (MVD). Representative IHC images (20×) for CD34 from untreated (A), polyclonal anti‐ELTD1 (pAb)‐treated (B) and monoclonal anti‐ETLD1 (mAb)‐treated animals (C) at tumour maximum volume (TV 120‐160 mm 2 ). Dark red/brown staining in the slides represents vessels in the tumour region highlighted by the arrows. D, MVD analysis for all of the treatment groups. The pAb and mAb treatments were able to significantly decrease MVD (**** P < .0001 for both). There was also a significant decrease in MVD for the mAb vs the pAb (** P < .01)

Article Snippet: Once tumours reached 6‐7 mm 3 (determined via MRI), mice were either left UT or were treated with 2 mg/kg of either polyclonal anti‐ELTD1 (Bioss, ETL/ELTD1 Polyclonal Antibody, bs‐13111R) or an optimized mAb against ELTD1 every 3‐4 days (treated M/Th, T/F, W/Sat).

Techniques: Staining

Journal: Journal of Cellular and Molecular Medicine

Article Title: Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model

doi: 10.1111/jcmm.14867

Figure Lengend Snippet: mAb ELTD1 probe has significantly higher binding specificity against the tumour. A, Molecular probe construct. Gd‐DTPA signal was used to detect the probe via MR imaging while the biotin tag allowed for localization in the tumour tissue post‐termination. B, Per cent relative expression of our molecular probes indicates a change in either T1 Relaxation or SI due to the presence of the Gd‐DTPA component. The mAb‐attached probe had significantly higher signal intensity and T1 relaxation time than the IgG control (T1: * P = .0307 (IgG vs pAb ELTD1 probe), *** P = .0002 (IgG vs mAb ELTD1 probe); SI: ** P = .008 (IgG vs mAb ELTD1 probe)), (C, D) localization and clustering of our monoclonal‐attached molecular probes (C) and non‐specific IgG‐attached molecular probe (D). E, Kinetics of the antibody‐attached probes, non‐specific IgG control, pAb and mAb against ELTD1. F‐H, Representative images (20×) stained with SA‐HRP to localize the non‐specific IgG‐attached probes (F), pAb‐attached probe (G) and mAb‐attached probe (H) at tumour maximum (TV: 120‐160 mm 2 ). The brown staining seen in the pAb‐ and mAb‐attached probes is the localized probes

Article Snippet: Once tumours reached 6‐7 mm 3 (determined via MRI), mice were either left UT or were treated with 2 mg/kg of either polyclonal anti‐ELTD1 (Bioss, ETL/ELTD1 Polyclonal Antibody, bs‐13111R) or an optimized mAb against ELTD1 every 3‐4 days (treated M/Th, T/F, W/Sat).

Techniques: Binding Assay, Construct, Imaging, Expressing, Staining

Journal: Journal of Cellular and Molecular Medicine

Article Title: Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model

doi: 10.1111/jcmm.14867

Figure Lengend Snippet: mAb treatment against ELTD1 decrease Notch1 levels. A‐D, Representative images (20×) of IHC stained tumours with Notch1 of untreated (A), pAb treatment (B), mAb treated (C) and contralateral control (D). E, Quantitative positivity Notch staining of the samples. mAb against ELTD1‐treated mice significantly lowered Notch levels when compared to both untreated and pAb‐treated animals. There was no significant difference between untreated vs pAb treatment, and mAb treatment and contralateral (healthy control). Contralateral (Cont) tissue Notch levels were significantly lower than untreated mice and pAb‐treated animals (* P = .0357 (mAb vs pAb), ** P = .0015 (Cont vs pAb), *** P = .0006 (UT vs mAb), **** P < .0001 (UT vs Cont))

Article Snippet: Once tumours reached 6‐7 mm 3 (determined via MRI), mice were either left UT or were treated with 2 mg/kg of either polyclonal anti‐ELTD1 (Bioss, ETL/ELTD1 Polyclonal Antibody, bs‐13111R) or an optimized mAb against ELTD1 every 3‐4 days (treated M/Th, T/F, W/Sat).

Techniques: Staining

Journal: Journal of Cellular and Molecular Medicine

Article Title: Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model

doi: 10.1111/jcmm.14867

Figure Lengend Snippet: A, Gene‐fold changes when comparing ELTD1 mAb‐treated mice to UT from up‐regulated (red) to down‐regulated (blue), obtained from RNA‐seq analysis. B, Gene‐gene correlations for the genes repressed after anti‐ELT1 mAb treatment. Red = positively correlated, green = negatively correlated. Using literature analysis software to categorize the groups of genes in terms of their published commonalities, they roughly fall into four categories (developmental genes, nestin‐related, cell proliferation/angiogenesis, astrocyte microglia inflammation)

Article Snippet: Once tumours reached 6‐7 mm 3 (determined via MRI), mice were either left UT or were treated with 2 mg/kg of either polyclonal anti‐ELTD1 (Bioss, ETL/ELTD1 Polyclonal Antibody, bs‐13111R) or an optimized mAb against ELTD1 every 3‐4 days (treated M/Th, T/F, W/Sat).

Techniques: RNA Sequencing Assay, Software